-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective: To evaluate the feasibility of reducing the dose of cyclophosphamide in patients with systemic sclerosis during high-dose chemotherapy and autologous stem cell transplantation before mobilizing chemotherap.
Methods: This single-center study retrospectively analyzed 32 patients with systemic sclerosis who underwent autologous stem cell transplantatio.
RESULTS: Higher doses of cyclophosphamide did not appear to be beneficial for stem cell collection, as there was no significant difference in stem cell yield between high and low doses of cyclophosphamide (2 vs 2*106/kg body weight after CD34+ enrichment .
Higher doses of cyclophosphamide were likely to have more side effects, but the difference was not statistically significan.
Lower body weight and body mass index (p<001) as well as pre-rituximab treatment (p<005) and cardiac involvement (p<001) may have negatively affected stem cell collection independently of the chosen regime.
Conclusions: The data from this study suggest that a reduced cyclophosphamide dose mobilization regimen appears feasibl.
Source:
Pecher AC, Ach KR, Vogel W, Henes J.